Published in Cancer Res on June 23, 2009
Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature (2013) 3.76
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol (2011) 2.88
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther (2011) 1.55
2-Deoxy-D-glucose treatment of endothelial cells induces autophagy by reactive oxygen species-mediated activation of the AMP-activated protein kinase. PLoS One (2011) 1.33
Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem (2010) 1.31
Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs. Aging (Albany NY) (2012) 1.31
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res (2010) 1.23
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol (2010) 1.21
The antifolates. Hematol Oncol Clin North Am (2012) 1.21
The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther (2012) 1.16
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biol Ther (2012) 1.12
Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol (2011) 1.12
Summary of the proceedings from the 10th annual meeting of molecularly targeted therapy in non-small cell lung cancer. J Thorac Oncol (2010) 1.11
AMPK and Akt determine apoptotic cell death following perturbations of one-carbon metabolism by regulating ER stress in acute lymphoblastic leukemia. Mol Cancer Ther (2011) 1.03
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol (2011) 1.00
Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. PLoS One (2013) 0.95
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget (2014) 0.92
The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab Dispos (2014) 0.89
Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphate. Mol Pharmacol (2012) 0.88
The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol (2013) 0.88
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget (2016) 0.88
Molecular Pathways: Is AMPK a Friend or a Foe in Cancer? Clin Cancer Res (2015) 0.87
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer (2010) 0.86
A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol (2013) 0.85
Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway. Biochem Biophys Res Commun (2011) 0.83
Phase I study of pemetrexed with sorafenib in advanced solid tumors. Oncotarget (2016) 0.81
Regulation of AMP-activated protein kinase by natural and synthetic activators. Acta Pharm Sin B (2015) 0.81
6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors. J Med Chem (2015) 0.81
AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells? Biochem Soc Trans (2013) 0.81
Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells. Mol Cancer Ther (2013) 0.81
In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol (2015) 0.80
Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization. Chembiochem (2012) 0.80
Differential regulation of autophagy and cell viability by ceramide species. Cancer Biol Ther (2015) 0.79
Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett (2011) 0.79
Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resist Updat (2010) 0.78
Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules. Onco Targets Ther (2014) 0.78
p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb. Mol Cancer Res (2015) 0.78
One-Carbon Metabolism in Health and Disease. Cell Metab (2016) 0.78
Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates. Mol Pharmacol (2016) 0.77
AMPK: Mechanisms of Cellular Energy Sensing and Restoration of Metabolic Balance. Mol Cell (2017) 0.76
AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. J Biol Chem (2015) 0.76
Generalized portrait of cancer metabolic pathways inferred from a list of genes overexpressed in cancer. Genet Res Int (2014) 0.76
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget (2016) 0.76
Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling. J Thorac Oncol (2010) 0.75
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. Oncotarget (2017) 0.75
A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer. Chemotherapy (2016) 0.75
Structural and Enzymatic Analysis of Tumor-Targeted Antifolates That Inhibit Glycinamide Ribonucleotide Formyltransferase. Biochemistry (2016) 0.75
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol (2007) 15.30
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol (1996) 4.06
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene (2006) 3.39
LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res (1997) 2.83
A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells (2003) 2.62
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem (2005) 2.57
Identification of phosphorylation sites in the translational regulator, PHAS-I, that are controlled by insulin and rapamycin in rat adipocytes. J Biol Chem (1997) 2.19
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther (2007) 2.05
THE ENZYMOLOGY OF FEEDBACK INHIBITION OF GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE BY PURINE RIBONUCLEOTIDES. J Biol Chem (1964) 1.96
Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A (1985) 1.65
A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem (1989) 1.39
Feedback control of purine biosynthesis by purine ribonucleotides. Nature (1959) 1.19
Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4-carboxamide riboside. Mol Cancer Ther (2006) 1.14
Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. Cancer Res (1976) 1.06
The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther (2006) 1.05
The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J Biol Chem (1989) 0.99
Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2'-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry (1978) 0.98
Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem (1988) 0.97
Biochemical determinants of tumor sensitivity to 5-fluorouracil: ultrasensitive methods for the determination of 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci U S A (1979) 0.97
Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Biochemistry (1997) 0.94
Resistance to methotrexate in thymidylate synthetase-deficient mutants of cultured mouse mammary tumor FM3A cells. Cancer Res (1981) 0.94
Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci U S A (1979) 0.93
Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer (1998) 0.90
Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol (1995) 0.89
Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity. Structure (1996) 0.88
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem (1989) 0.87
Catalytic mechanism of the cyclohydrolase activity of human aminoimidazole carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase. Biochemistry (2004) 0.84
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics. Clin Lung Cancer (2007) 0.83
DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc Natl Acad Sci U S A (2011) 2.21
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther (2007) 2.05
Transducing particles of Staphylococcus aureus pathogenicity island SaPI1 are comprised of helper phage-encoded proteins. J Bacteriol (2007) 1.53
An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell (2012) 1.43
Modifications of human histone H3 variants during mitosis. Biochemistry (2005) 1.29
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res (2010) 1.23
Molecular basis for chromatin binding and regulation of MLL5. Proc Natl Acad Sci U S A (2013) 1.15
Folate metabolism in plants: an Arabidopsis homolog of the mammalian mitochondrial folate transporter mediates folate import into chloroplasts. J Biol Chem (2005) 1.13
Tandem PHD fingers of MORF/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin. J Mol Biol (2012) 1.05
A mutation inactivating the mitochondrial inner membrane folate transporter creates a glycine requirement for survival of chinese hamster cells. J Biol Chem (2004) 0.93
Dido3 PHD modulates cell differentiation and division. Cell Rep (2013) 0.91
A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem (2003) 0.91
Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res (2002) 0.89
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy (2011) 0.86
Tetrahydrofolate recognition by the mitochondrial folate transporter. J Biol Chem (2011) 0.85
Mouse folylpoly-gamma-glutamate synthetase isoforms respond differently to feedback inhibition by folylpolyglutamate cofactors. Biochemistry (2002) 0.85
A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression. Mol Cell Biol (2007) 0.85
Probing the mechanism of the hamster mitochondrial folate transporter by mutagenesis and homology modeling. Biochemistry (2007) 0.85
Structures of RNA polymerase II complexes with Bye1, a chromatin-binding PHF3/DIDO homologue. Proc Natl Acad Sci U S A (2013) 0.82
Concentration-dependent processivity of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase. Biochemistry (2008) 0.81
Humanizing mouse folate metabolism: conversion of the dual-promoter mouse folylpolyglutamate synthetase gene to the human single-promoter structure. FASEB J (2014) 0.75